Company Reports Revenue of $10 billion
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the quarter was $10 billion
Based in ABBOTT PARK, Illinois, ABBOTT LABORATORIES operates in the MANUFACTURING sector.
In the first quarter of 2024, the company reported net sales of $9.964 million, compared to $9.747 million in the same period in 2023. The revenue increased slightly year-over-year.
Cost of products sold, excluding amortization of intangible assets, was $4.463 million in the current quarter, up from $4.331 million in the previous year's quarter. Amortization of intangible assets decreased from $491 million to $472 million.
Research and development expenses rose to $684 million from $654 million, while selling, general, and administrative costs also increased to $2.959 million from $2.762 million. Total operating costs and expenses amounted to $8.578 million in the current quarter, compared to $8.238 million in the same period last year.
Operating earnings decreased to $1.386 million in the first quarter of 2024 from $1.509 million in the first quarter of 2023.
Interest expense dropped to $141 million from $153 million, while interest income improved to ($80) million from ($101) million. Net foreign exchange recorded no gain or loss in the current quarter, compared to a $6 million loss in the previous year's quarter.
Earnings before taxes decreased to $1.436 million from $1.562 million. Taxes on earnings were $211 million in the first quarter of 2024, down from $244 million in the first quarter of 2023.
The company reported net earnings of $1.225 million in the current quarter, a decline compared to $1.318 million in the same period last year.
Basic earnings per common share remained constant at $0.70, as did diluted earnings per common share at $0.70. The average number of common shares outstanding used for basic and diluted earnings per common share also remained relatively stable year-over-year.
USInMinutes/IndiaInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to more news alerts here. Although care is taken to ensure accuracy of the data, the article does not intend to replace user diligence while taking decisions of financial or legal implications